Navigation Links
FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
Date:11/4/2010

INDIANAPOLIS, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. This is the fifth indication the FDA has approved for Cymbalta.

Cymbalta, which has been shown to significantly reduce chronic low back pain and chronic pain due to osteoarthritis, is a non-narcotic pain reliever that is meant to be taken once a day, every day by people with these pain conditions.

"People with chronic musculoskeletal pain often struggle to find a medication that works for them. The approval of Cymbalta for chronic musculoskeletal pain by the FDA gives doctors another option to help an underserved and suffering group of patients," said Michael Clark, M.D., MPH, director, Chronic Pain Treatment Program, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins Medical Institutions.

Although the exact way that Cymbalta works to reduce chronic musculoskeletal pain is unknown, it is believed that Cymbalta helps lessen pain by enhancing the body's natural pain suppressing system by increasing the activity of serotonin and norepinephrine in the brain and spinal cord.

In chronic musculoskeletal pain clinical studies, the most commonly observed adverse events (those occurring in at least 5 percent of study participants taking Cymbalta and at least twice the rate of placebo) in Cymbalta-treated patients with chronic low back pain were nausea, dry mouth, insomnia, sleepiness, constipation, dizziness and fatigue. The most commonly observed adverse events in Cymbalta-treated patients with chronic pain due to osteoarthritis were nausea, fatigue and constipation.

"It's important that p
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves New Indication for Afinitor
2. FDA Approves Teflaro for Bacterial Infections
3. FDA Approves Latuda to Treat Schizophrenia in Adults
4. FDA Approves Additional Medical Indication for Sprycel
5. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
6. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
7. FDA Approves Botox to Treat Chronic Migraine
8. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
9. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
10. FDA Approves Combination Contraceptive Containing a Folate
11. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... 2015 Educating the community continues to ... the Advancement of Wound Care (AAWC), which was ... AAWC,s corporate partners, the Association provides medical professionals ... AAWC website at http://aawconline.org/education-for-the-generalist/ . The portal ... links to various CME/CEU educational programs. This education ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Companies"  to their offering.  ... (RNAi) or gene silencing involves the use ... the cell, this material is processed into ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... N.Y., July 17 Strong National,Museum of Play ... of the,American Journal of Play, the first interdisciplinary ... The inaugural issue enters the scholarly scene ... the most prominent national,researchers and writers in the ...
... to data from other, technologies -, ... Bradmer Pharmaceuticals Inc.,(TSX: BMR), a biopharmaceutical company dedicated ... released progression free,survival (PFS) data from two previously ... (GBM) patients. As an exploratory,endpoint of the single ...
Cached Medicine Technology:Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008 2Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 2Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 3Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 4Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 5
(Date:5/29/2015)... Johnson & Johnson and its ... lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with a California ... use of the antipsychotic medication. According to court ... third bellwether trial to involve male breast growth ... Pennsylvania’s Philadelphia Court of Common Pleas, where more ...
(Date:5/29/2015)... May 29, 2015 A group of doctors ... joined the national effort to teach this “new math” to ... U.S. have been “sickened” by the recent implementation of Common ... or hate it, Common Core is now a reality in ... Parents are now seeking ways to improve common core ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
(Date:5/29/2015)... 29, 2015 The print component of ... circulation of approximately 250,000 and an estimated readership of ... vast social media strategy, and across a network of ... digital version of the campaign, click here. ... publication. Inside, the actress, model and producer details her ...
(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... readers on the “beauty of protection”. Skin Health ... through USA Today within the markets of New York, ... reach an estimated 750,000 readers. Its digital counterpart will ... online content hubs. To read more the Skin Health ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Doctors Discover a Cure for the Common Core 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2
... According to a new study it is observed that ... effects for adults diagnosed with bacterial meningitis. Dexamethasone is ... patients.// The death rate among adults diagnosed with bacterial ... pneumonia. Researchers from the Academic Medical Center in Amsterdam ...
... to a new study researchers observe that stress hormones ... HPA (hypothalamus-pituitary-adrenal) axis is a hormonal system that helps ... end result is the production of the stress hormone ... is characterized by aches, pains and overwhelming tiredness. It's ...
... that a new topical medication can effectively treat signs of ... that in a long-term study of tazarotene cream, has ... 55 percent// of those tested, and it continued to show ... radiation from the sun is known to have numerous ill ...
... University observed that a chest compression belt outperforms manual ... someone has a cardiac arrest, it's vital to get ... as possible. Usually this is done by applying chest ... but these are usually not available in those vital ...
... in University of Boston observe that brain imaging sheds new ... apnoea, a person stops breathing, momentarily, many times during the ... at the back of the throat, causing upper airway obstruction. ... daytime sleepiness. It may also be a risk factor for ...
... emphysema does not help the sickest patients, according to ... lungs - the alveoli - are progressively destroyed,// leaving ... do everyday activities like climbing stairs or carrying their ... lung reduction surgery was beneficial for people with emphysema. ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: